Forest To Use New Data To Promote Lexapro In Face Of Paxil CR Relaunch
This article was originally published in The Pink Sheet Daily
Executive Summary
Lexapro market share gain is behind expectations because of the market reentry of GlaxoSmithKline’s Paxil CR, increased detailing by antidepressant competitors and more aggressive promotion of generics by payors.